PHILADELPHIA, May 30, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that David Walton, who has nearly two decades of strategic healthcare marketing experience, has joined Echo Therapeutics' management team at a critical stage in company growth. Mr. Walton will report to CEO Patrick Mooney, M.D.
David Walton joins as Vice President of Marketing and Commercial Development, leading global strategic marketing planning for Echo's Symphony tCGM System and other new products in the Company's growth strategy.
"We are extremely pleased to welcome David to Echo's management team. Dave brings an extensive track record of business strategy, healthcare marketing, and product development expertise to Echo," said Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "We look forward to benefiting from Dave's substantial knowledge to lead Symphony from product development to global commercialization."
Mr. Walton brings 17 years of healthcare marketing and strategic planning experience to Echo. He joins Echo from Johnson & Johnson's Diabetes Care Franchise, where he most recently served as Worldwide Director, Global Strategic Marketing for Insulin Delivery and Continuous Glucose Monitoring products at LifeScan. During his 11 years at J&J, he worked in a number of therapeutic areas, including Diabetes, ADHD, Parkinson's Disease and Oncology and has received several J&J Standards of Leadership Awards. Prior to J&J, Mr. Walton spent 6 years in healthcare consulting at Deloitte Consulting and Bogart Delafield Ferrier working on various strategy and marketing engagements for health plans, hospital systems and pharmaceutical, biotech and medical device clients. He earned his BA degree in Psychology from Princeton University and an MBA in Healthcare Management from the Wharton School at the University of Pennsylvania.About Echo Therapeutics Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts